Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Yan Wu, Feiran Wang, Chenguang Shen, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

COVID-19 Docking Server: a meta server for docking small molecules, peptides and antibodies against potential targets of COVID-19
Ren Kong, Guangbo Yang, Rui Xue, et al.
Bioinformatics (2020) Vol. 36, Iss. 20, pp. 5109-5111
Open Access | Times Cited: 167
COVID-19: Progress in diagnostics, therapy and vaccination
Xue Liu, Chao Liu, Gang Liu, et al.
Theranostics (2020) Vol. 10, Iss. 17, pp. 7821-7835
Open Access | Times Cited: 148
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Yiska Weisblum, Fabian Schmidt, Fengwen Zhang, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 130
Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity
Jorge Carrillo, Nuria Izquierdo‐Useros, Carlos Ávila‐Nieto, et al.
Biochemical and Biophysical Research Communications (2020) Vol. 538, pp. 187-191
Open Access | Times Cited: 114
Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications
Yufeng Wei, Rameen Shah
Pharmaceuticals (2020) Vol. 13, Iss. 7, pp. 155-155
Open Access | Times Cited: 112
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Yunlong Cao, Jing Wang, Fanchong Jian, et al.
Nature (2021)
Open Access | Times Cited: 97
Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma
Lluc Farrera‐Soler, Jean‐Pierre Daguer, Sofía Barluenga, et al.
PLoS ONE (2020) Vol. 15, Iss. 9, pp. e0238089-e0238089
Open Access | Times Cited: 95
Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
Tyler N. Starr, Allison J. Greaney, Sarah K. Hilton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 84
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Fabian Schmidt, Yiska Weisblum, Frauke Muecksch, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 82
Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2In VitroVirus Neutralization in Convalescent Plasma
Eric Salazar, Suresh V. Kuchipudi, Paul A. Christensen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 70
Blocking of the High-Affinity Interaction-Synapse Between SARS-CoV-2 Spike and Human ACE2 Proteins Likely Requires Multiple High-Affinity Antibodies: An Immune Perspective
Indu Khatri, Frank J. T. Staal, Jacques J. M. van Dongen
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 53
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
Frauke Muecksch, Yiska Weisblum, Christopher O. Barnes, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 45
CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses
Sallieu Jalloh, Judith Olejnik, Jacob Berrigan, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 10, pp. e1010479-e1010479
Open Access | Times Cited: 31
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
Hatem A. Elshabrawy
Vaccines (2020) Vol. 8, Iss. 2, pp. 335-335
Open Access | Times Cited: 45
A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds
Lara Schöler, Vu Thuy Khanh Le‐Trilling, Mareike Eilbrecht, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 42
E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody
Sandipan Chakraborty
International Immunopharmacology (2021) Vol. 102, pp. 108424-108424
Open Access | Times Cited: 39
Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS–CoV–2 Spike
Carl Graham, Jeffrey Seow, Isabella Huettner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 32
What do we know about the antibody responses to SARS-CoV-2?
Francisco Alejandro Lagunas‐Rangel, Venice Chávez‐Valencia
Immunobiology (2021) Vol. 226, Iss. 2, pp. 152054-152054
Open Access | Times Cited: 27
CoV-AbDab: the Coronavirus Antibody Database
Matthew I. J. Raybould, Aleksandr Kovaltsuk, Claire Marks, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 28
Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
Nicholas K. Hurlburt, Yu-Hsin Wan, Andrew B. Stuart, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 26
Initial determination of COVID-19 seroprevalence among outpatients and healthcare workers in Minnesota using a novel SARS-CoV-2 total antibody ELISA
Stefani N. Thomas, Ghaith Altawallbeh, Christopher Zaun, et al.
Clinical Biochemistry (2021) Vol. 90, pp. 15-22
Open Access | Times Cited: 22
Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain
Fisayo A. Olotu, Kehinde F. Omolabi, Mahmoud E. S. Soliman
Informatics in Medicine Unlocked (2020) Vol. 21, pp. 100451-100451
Open Access | Times Cited: 22
Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment
Jing Ouyang, Stéphane Isnard, John Lin, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 18
Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection
Joong Sik Eom, Michael G. Ison, Anca Streinu‐Cercel, et al.
Research Square (Research Square) (2021)
Closed Access | Times Cited: 14
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
Pauline Maisonnasse, Yoann Aldon, Aurélien Marc, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top